Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi

CITIRIK, Mehmet; ÖZCAN, Pehmen Yasin

Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi

Pehmen Yasin ÖZCAN, (Çocuk Hastalıkları Hastanesi, Göz Kliniği, Şanlıurfa, Türkiye)

Mehmet ÇITIRIK (Ankara Ulucanlar Göz Eğitim ve Araştırma Hastanesi, Ankara, Türkiye)

Retina-Vitreus

1 0

Yıl: 2016 Cilt: 24 Sayı: 4 Sayfa Aralığı: 271 - 279 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi

Öz:

Prematüre retinopatisi (PR) erken doğan bebeklerde retinal damarların anormal gelişmesine ve potansiyel olarak körlüğe yol açabilen bir hastalıktır. Doğru yönetim ile kötü görsel sonuç görülme oranı belirgin şekilde azaltılmıştır. PR tedavisi için kullanılan vasküler endotelyal büyüme faktörü inhibitörleri retinanın vaskülarizasyonuna olanak sağlamasına rağmen, günümüzde şiddetli PR için altın standart tedavi yöntemi lazer fotokoagülasyondur. Sınıflandırma ve tarama protokolleri en uygun yönetim modeline ulaşmak için sık sık güncellenmektedir. Bu yazıda güncel prematüre retinopatisinde güncel sınıflandırma, tarama, muayene yöntemleri ve tedaviden bahsedilecektir.

Anahtar Kelime:

Konular: Göz Hastalıkları

Current Classification, Screening, Examination Methods, and Treatment in Retinopathy of Prematurity

Öz:

Retinopathy of prematurity is a potentially blinding disease caused by abnormal development of retinal blood vessels in premature infants. With proper management, the incidence of poor visual outcome has been markedly decreased. Although vascular endothelial growth factor inhibitors for the treatment of ROP may allow to continue vascularization of the retina, laser photocoagulation is the current gold standart treatment for severe ROP. Classification and screening protocols are frequently updated for reaching the most appropriate management. This article mentions about current classification, screening, examination methods, and treatment in retinopathy of prematurity.

Anahtar Kelime:

Konular: Göz Hastalıkları

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Bibliyografik

Terry TL. Extreme prematurity and fibroblastic overgrowth of persis- tent vascular sheath behind each crystalline lens: (1) preliminary report. Am J Ophthalmol 1942;25:203-4.
Niranjan HS, Benakappa N, Reddy KR, et al. Retinopathy of Prema- turity- Promising Newer Modalities of Treatment. Indian Pediatrics. 2012;49:139-143.
Fierson WM; American Academy of Pediatrics Section on Ophthalmo- logy; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013;131:189-95.
International Committee for the Classification of Retinopathy of Pre- maturity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991-99.
Shah PK, Prabhu V, Karandikar SS, et al. Retinopathy of prematurity : Past, present and future. World J Clin Pediatr 2016;5:35-46.
Ng EY, Lanigan B, O'Keefe M. Fundus fluorescein angiography in the screening for and management of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus . 2006;43:85-90.
Yokoi T, Hiraoka M, Miyamoto M, et al. Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography. Ophthalmology. 2009;116:1377-1382.
Dubis AM, Costakos DM, Subramaniam CD, et al. Evaluation of nor- mal human foveal development using optical coherence tomography and histologic examination. Arch Ophthalmol.2012;130:1291-300 .
Yanni SE, Wang J, Chan M, et al. Foveal avascular zone and foveal pit formation after preterm birth. Br J Ophthalmol. 2012;96:961-966 .
Lepore D, Molle F, Pagliara MM, et al. Atlas of fluorescein angiograp- hic findings in eyes undergoing laser for retinopathy of prematurity. Ophthalmology. 2011;118:168-175.
Hammer DX, Iftimia NV, Ferguson RD, et al. Foveal fine structu- re in retinopathy of prematurity: an adaptive optics Fourier doma- in optical coherence tomography study. Invest Ophthalmol Vis Sci . 2008;49:2061-70.
Gursoy H, Bilgec MD, Erol N, et al. The macular findings on spect- ral-domain optical coherence tomography in premature infants with or without retinopathy of prematurity. Int Ophthalmol. 2016. [baskıda].
Maldonado RS, O'Connell RV, Sarin N, et al. Dynamics of human foveal development after premature birth. Ophthalmology.2011;118:2315-25.
Vinekar A, Avadhani K, Sivakumar M, et al. Understanding clinically undetected macular changes in early retinopathy of prematurity on spectral domain optical coher- ence tomography. Invest Ophthalmol Vis Sci. 2011;52:5183-88 .
Erol MK, Ozdemir O, Turgut Coban D, et al. Macular findings obtained by spectral domain optical coherence tomography in retinopathy of pre- maturity. J Ophthalmol .2014;2014:468-653.
Wang J, Spencer R, Leffler JN, et al. Characteristics of peripapillary re- tinal nerve fiber layer in preterm children. Am J Ophthalmol 2012;153: 850-5 e851.
Tariq YM, Pai A, Li H,et al. Association of birth parameters with OCT measured macular and retinal nerve fiber layer thickness. Invest Oph- thalmol Vis Sci 2011;52:1709-15.
Akerblom H, Holmstrom G, Eriksson U, et al. Retinal nerve fibre layer thickness in school-aged prematurely-born children compared to child- ren born at term. Br J Ophthalmol 2012;96:956-60.
Park KA, Oh SY. Retinal nerve fiber layer thickness in prematurity is correlated with stage of retinopathy of prematurity. Eye (Lond). 2015;29:1594-602.
Park KA, Oh SY. Analysis of spectral-domain optical coherence to- mography in preterm children: retinal layer thickness and choroidal thickness profiles. Invest Ophthalmol Vis Sci 2012;53:7201-7.
Akerblom H, Larsson E, Eriksson U, et al. Central macular thickness is correlated with gestational age at birth in prematurely born children. Br J Ophthalmol 2011; 95:799-803.
Yanni SE, Wang J, Chan M, et al. Foveal avascular zone and foveal pit formation after preterm birth. Br J Ophthalmol 2012;96:961-6.
Wang J, Spencer R, Leffler JN, et al. Critical period for foveal fine structure in children with regressed retinopathy of prematurity. Retina 2012;32:330-339.
Jalali S, Anand R, Kumar H, et al. Programme planning and screening strategy in retinopathy of prematurity. Indian J Ophthalmol 2003;51:89-99.
Wu C, Vanderveen DK, Hellström A, et al. Longitudinal postnatal we- ight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol. 2010;128:443-47.
Wu C, Löfqvist C, Smith LE, et al. for the WINROP Consortium. Im- portance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Oph- thalmol. 2012;130:992-99.
Wu C, Löfqvist C, Smith LE, et al. for the WINROP Consortium. Im- portance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Oph- thalmol. 2012;130:992-99.
Eckert GU, Fortes Filho JB, Maia M, et al. A predictive score for re- tinopathy of prematurity in very low birth weight preterm infants. Eye (Lond). Mar; 2012;26:400-406.
Binenbaum G, Ying GS, Quinn GE, et al. A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain. Pediatrics. 2011;127:607-614.
Binenbaum G, Ying GS, Quinn GE, et al. The CHOP postnatal weight gain, birth weight, and gestational age retinopathy of prematurity risk model. Arch Ophthalmol. 2012;130:1560-5.
Van Sorge AJ, Schalij-Delfos NE, Kerkhoff FT, et al. Reduction in scre- ening for retinopathy of prematurity through risk factor adjusted inclu- sion criteria. Br J Ophthalmol 2013;97:1143-7.
Ying GS, Quinn GE, Wade KC, et al. e-ROP Cooperative Group. Predictors for the development of referral-warranted retinopathy of prematurity in the telemedicine approaches to evaluating acute-pha- se retinopathy of prematurity (e-ROP) study. JAMA Ophthalmol 2015;133:304-11.
Fierson WM, Capone A Jr; Telemedicine for evaluation of retinopathy of prematurity. American Academy of Pediatrics Section on Ophthal- mology; American Academy of Ophthalmology, American Association of Certified Orthoptists. Pediatrics. 2015;135:238-54.
Hutchinson AK, Melia M, Yang MB, et al. Clinical Models and Al- gorithms for the Prediction of Retinopathy of Prematurity: A Re- port by the American Academy of Ophthalmology. Ophthalmo- logy.2016;123:804-16.
Tasman W. Cryotherapy for Retinopathy of Prematurity Cooperative Group Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988;106:471-9.
Cryotherapy for Retinopathy of Prematurity Cooperative Group Multi- center trial of cryotherapy for retinopathy of prematurity: ophthalmo- logical outcomes at 10 years. Arch Ophthalmol. 2001;119:1110-18 .
Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group Final results of the early treatment for retinopathy of prematu- rity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102: 233-248; discussion 248-50.
Good WV, Hardy RJ, Dobson V, et al. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol. 2010;128:663-71 .
Christiansen SP, Dobson V, Quinn GE,et al. Progression of type 2 to type 1 retinopathy of prematurity in the Early Treatment for Retino- pathy of Prematurity Study. Arch Ophthalmol. 2010;128:461-465.
Choi MY, Park IK, Yu YS. Long term refractive outcome in eyes of pre- term infants with and without retinopathy of prematurity: Comparison of keratometric value, axial length, anterior chamber depth, and lens thickness. Br J Ophthalmol. 2000;84:138-143.
Knight-Nanan DM, Algawi K, Bowell R, et al. Advanced cicatricial re- tinopathy of prematurity-outcome and complications. Br J Ophthalmol. 1996;80:343-345.
Maly E. Frequency and natural history of retinopathy of prematurity (ROP). A prospective study in a Swedish city 1986-1990. Acta Oph- thalmol Suppl. 1993;210:52-55.
Kaiser RS, Trese MT, Williams GA, et al. Adult retinopathy of pre- maturity: Outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology. 2001;108:1647-1653.
Cernichiaro-Espinosa LA, Olguin-Manriquez FJ, Henaine-Berra A, et al. New insights in diagnosis and treatment for Retinopathy of Prema- turity. Int Ophthalmol. 2016. [Baskıda]
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Group B-RC. Efficacy of intravitreal bevacizumab for stage 3 ? retinopathy of prematurity. N Engl J Med. 2011;364:603-15.
Pertl L, Steinwender G, Mayer C, et al. A systematic review and meta- analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treat- ment of retinopathy of prematurity. PLoS ONE. 2015;10:e0129383.
Vinekar A, Jayadev C, Mangalesh S, et al. Comparing the outcome of single versus multiple session laser pho- toablation of flat neovascu- larization in zone 1 aggressive posterior retinopathy of prematurity: a prospective ran- domized study. Retina. 2015;35:2130-6.
Isaac M, Mireskandari K, Tehrani N. Treat- ment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS 2015;19:140-4.
Yetik H, Gunay M, Sirop S, et al. Intravitreal bevacizumab monothe- rapy for type- 1 prethreshold, threshold, and aggressive posterior reti- nopathy of prematurity-27 month follow-up results from Turkey. Grae- fes Arch Clin Exp Ophthalmol 2015;253:1677-83.
Ozcan PY, Con R, Celik HT. [Incidence, risk factors and treatment outcomes of retinopathy of prematurity in the southeastern Anatolian region province of Şanlıurfa in Turkey]. Turkiye Klinikleri J Med Sci 2015;35:240-7.
Lee JY, Chae JB, Yang SJ, et al. Effects of intravitreal and laser in re- tinopathy of prematurity theraphy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010;248:1257-62.
Menke MN, Framme C, Nelle M, et al.. Intravitreal ranibizumab mo- notherapy to treat retinopathy of prematu- rity zon II, stage 3 with plus disease. BMC Ophthalmol 2015;15:20.
Castellanos MA, Schwartz S, García-Aguirre G, et al. Short-term out- come after intravitreal ranibizumab injections for the treatment of reti- nopathy of prematurity. Br J Ophthalmol. 2013;97:816-9.
Arámbulo O, Dib G, Iturralde J, et al. Intravitreal ranibizumab as a pri- mary or a combined treatment for severe retinopathy of prematurity. Clin Ophthalmol. 2015;9:2027-32.
Erol MK, Coban DT, Sari ES, et al. Comparison of intravitreal ranibi- zumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:340-3
Erol MK, Coban DT, Özdemir Ö, et al. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retino- pathy of Prematurity. J Pediatr Ophthalmol Strabismus. 2015;52:152-4.
Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prema- turity after bevacizumab injection. Arch Ophthalmol. 2012; 130:1001- 6. Erratum in: Arch Ophthalmol. 2013;13:212. Comment in: JAMA Ophthalmol. 2013;131:546-7. JAMA Ophthalmol. 2013;131:544-5.
Salman AG, Said AM. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retino- pathy of prematurity. Ophthalmic Res. 2015;53:15-20.
Isaac M, Tehrani N, Mireskandari K; Medscape.Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizu- mab: implications for follow-up. Eye (Lond). 2016;30:333-41.
Coats DK, Miller AM, Brady McCreery KM, et al. Involution of thres- hold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology 2004;111:1894-8.
Gupta MP, Chan RV, Anzures R, et al. Imaging & Informatics in ROP Research Consortium. Practice Patterns in Retinopathy of Prematurity Treatment for Disease Milder Than Recommended by Guidelines. Am J Ophthalmol. 2016;163:1-10.
Carvounis PE, Poll J, Weikert MP, et al. Refractive outcomes of lens- sparing vitrectomy for retinopathy of prematurity. Arch Ophthalmol. 2010;128:843-6.
Nudleman E, Robinson J, Rao P, et al. Long-term outcomes on lens clarity after lens-sparing vitrectomy for retinopathy of prematurity. Ophthalmology. 2015;122:755-759.
Lakhanpal RR, Davis GH, Sun RL, et al. Lens clarity after 3-port lens- sparing vitrectomy in stage 4A and 4B retinal detachments secondary to retinopathy of prematurity. Arch Ophthalmol.2006;124:20-3.
Kychenthal A, Dorta P .Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina 30(4 Suppl):S32-S36.
Hellstrom A, Engstrom E, Hard AL, et al. Postnatal serum insulinlike growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003;112:1016-20.
Wilson DC, Cairns P, Halliday HL, et al. Randomised controlled trial of an aggressive nutritional regimen in sick very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 1997;77:F4-11.
Löfqvist C, Niklasson A, Engström E, et al. A pharmacokinetic and do- sing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res. 2009;65:574-79.
Kojima H, Otani A, Oishi A, et al. Granulocyte colony-stimulating fac- tor attenuates oxidative stress-induced apoptosis in vascular endothe- lial cells and exhibits functional and morphologic protective effect in oxygen-induced retinopathy; Blood. 2011;117:1091-100.
Bhola R, Purkiss T, Hunter S, et al. Effect of granulocyte colony-stimu- lating factor on the incidence of threshold retinopathy of prematurity. J AAPOS. 2009;13:450-3.
Guma M, Rius J, Karen X,et al. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. PNAS. 2009;106;8760-5.
Kwinta P, Pietrzyk JJ. Retinopathy of prematurity: is genetic predispo- sition an important risk factor? Exp Rev Ophthalmol. 2007;2:275-83.
Phelps DL, Rosenbaum AL, Isenberg SJ, et al. Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, control- led, double-masked trial. Pediatrics. 1987;79:489-500.
Rosenbaum AL, Phelps DL, Isenberg SJ, et al. Retinal hemorrhage in retinopathy of prematurity associ- ated with tocopherol treatment. Ophthalmology. 1985;92:1012-1014.
Beharry KD, Valencia GB, Lazzaro DR, et al. Pharmacologic interven- tions for the prevention and treatment of retinopathy of prematurity. Semin Perinatol. 2016;40:189-202.
Mactier H, Weaver LT. Vitamin A and preterm infants: what we know, what we don't know, and what we need to know. Arch Dis Child Fetal Neonatal Ed. 2005;90:F103-F108.
Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Da- tabase Syst Rev. 2002:CD000501.
Russell GA, Cooke RW. Randomised controlled trial of allopurinol prophylaxis in very preterm infants. Arch Dis Child Fetal Neonatal Ed. 1995;73:F27-F31.
Avila-Vazquez M, Maffrand R, Sosa M, et al. Treatment of retinopathy of prematurity with topical ketorolac tromethamine: a preliminary study. BMC Pediatr. 2004;7:4-15.
Giannantonio C, Purcaro V, Cota F, et al. Effectiveness of ketorolac tromethamine in prevention of severe retino- pathy of prematurity. J Pediatr Ophthalmol Strabismus. 2011;48:247-251.
Higgins RD, Mendelsohn AL, et al. Antenatal dexamethasone and decreased severity of retinopathy of prematurity. Arch Ophthalmol. 1998;116:601-05.
Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing broncho- pulmonary dysplasia in preterm infants: a systematic review. Neonatology. 2010;98:217-24.
Cavalli C, Teng C, Battaglia FC, et al. Free sugar and sugar alcohol concentrations in human breast milk. J Pediatr Gastroenterol Nutr. 2006;42:215-21.
Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357:1893-19028.
Hsu SJ, Lee FY, Wang SS, et al. Caffeine ameliorates hemo- dynamic derangements and portosystemic collaterals in cirrhotic rats. Hepato- logy. 2015;61:1672-84.
Liu WH, Chang LS. Caffeine induces matrix metal- loproteinase-2 (MMP-2) and MMP-9 down-regulation in human leukemia U937 cells via Ca2?/ROS-mediated suppres- sion of ERK/c-fos pathway and acti- vation of p38 MAPK/c-jun pathway. J Cell Physiol. 2010;224:775-85.
Fiebich BL, Lieb K, Hüll M, et al Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E(2) synthesis in rat microglial cells. Neuropharmacology. 2000;39:2205-13.
Léauté-Labrèze C. Propranolol in infantile hemangiomas. Arch Pediatr. 2015;22:452-5.
Filippi L, Cavallaro G, Bagnoli P, et al. Oral propranolol for retino- pathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163:1570-7.
Bührer C, Bassler D. Oral propranolol: a new treatment for infants with retinopathy of prematurity? Neonatology. 2015;108:49-52.
Makhoul IR, Peleg O, Miller B, et al. Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind pros- pective study. Arch Dis Child. 2013;98:565-7.

APA	ÖZCAN P, CITIRIK M (2016). Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. , 271 - 279.
Chicago	ÖZCAN Pehmen Yasin,CITIRIK Mehmet Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. (2016): 271 - 279.
MLA	ÖZCAN Pehmen Yasin,CITIRIK Mehmet Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. , 2016, ss.271 - 279.
AMA	ÖZCAN P,CITIRIK M Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. . 2016; 271 - 279.
Vancouver	ÖZCAN P,CITIRIK M Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. . 2016; 271 - 279.
IEEE	ÖZCAN P,CITIRIK M "Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi." , ss.271 - 279, 2016.
ISNAD	ÖZCAN, Pehmen Yasin - CITIRIK, Mehmet. "Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi". (2016), 271-279.

APA	ÖZCAN P, CITIRIK M (2016). Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. Retina-Vitreus, 24(4), 271 - 279.
Chicago	ÖZCAN Pehmen Yasin,CITIRIK Mehmet Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. Retina-Vitreus 24, no.4 (2016): 271 - 279.
MLA	ÖZCAN Pehmen Yasin,CITIRIK Mehmet Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. Retina-Vitreus, vol.24, no.4, 2016, ss.271 - 279.
AMA	ÖZCAN P,CITIRIK M Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. Retina-Vitreus. 2016; 24(4): 271 - 279.
Vancouver	ÖZCAN P,CITIRIK M Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi. Retina-Vitreus. 2016; 24(4): 271 - 279.
IEEE	ÖZCAN P,CITIRIK M "Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi." Retina-Vitreus, 24, ss.271 - 279, 2016.
ISNAD	ÖZCAN, Pehmen Yasin - CITIRIK, Mehmet. "Prematüre Retinopatisinde Güncel Sınıflandırma, Tarama, Muayene Yöntemleri ve Tedavi". Retina-Vitreus 24/4 (2016), 271-279.